Resistance artery mechanics and composition in angiotensin II-infused mice: effects of cyclooxygenase-1 inhibition

Eur Heart J. 2012 Sep;33(17):2225-34. doi: 10.1093/eurheartj/ehr138. Epub 2011 May 23.

Abstract

Aims: The aim of this study was to investigate the role of cyclooxygenase (COX)-1 on vascular alterations in structure, mechanics, and extracellular matrix (ECM) components induced by angiotensin (Ang) II in mesenteric arteries from wild-type (WT) and COX-1 knockout (COX-1(-/-)) mice.

Methods and results: Animals were infused with vehicle or Ang II (400 ng/kg/min, s.c.) ± SC-560 (COX-1 inhibitor), DFU (COX-2 inhibitor), or SQ-29548 (TP receptor antagonist). After 2 weeks, vessels were isolated and exposed to intraluminal pressures (3-140 mmHg, pressurized myograph) to determine mechanical properties. Angiotensin II-induced vascular hypertrophic remodelling in WT was reversed by SC-560 or SQ-29548, but unaffected by DFU. Angiotensin II increased vessel stiffness (P< 0.01), this effect being ameliorated by SC-560 or SQ-29548, but unmodified by DFU. Angiotensin II failed to modify vessel elasticity in COX-1(-/-) mice. In WT vessels, Ang II enhanced COX-1 immunostaining, induced collagen and fibronectin depositions and decreased elastin content (P< 0.01). These effects were reversed by SC-560 or SQ-29548, but unaffected by DFU. In COX-1(-/-) mice, Ang II did not affect ECM contents. In WT, Ang II increased COX-1 and decreased COX-2 expression, and enhanced the vascular release of 6-keto-PGF1α which was prevented by COX-1 blockade. Human coronary artery smooth muscle cells, incubated with Ang II, showed an increased expression of procollagen I, which was abrogated by SC-560 or SQ-29548.

Conclusion: Angiotensin II-induced alterations of resistance arteries in structure, mechanics, and ECM composition were prevented by COX-1 inhibition and TP receptor antagonism, indicating that Ang II-mediated vascular damage is mediated by COX-1-derived prostanoid prostacyclin, activating TP receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / biosynthesis
  • Analysis of Variance
  • Angiotensin II / pharmacology*
  • Animals
  • Biomechanical Phenomena
  • Blood Pressure / physiology
  • Bridged Bicyclo Compounds, Heterocyclic
  • Cells, Cultured
  • Collagen Type I / metabolism
  • Coronary Vessels / drug effects
  • Coronary Vessels / physiology
  • Cyclooxygenase 1 / metabolism*
  • Cyclooxygenase Inhibitors / pharmacology*
  • Dinoprost / analogs & derivatives
  • Dinoprost / biosynthesis
  • Elastin / metabolism
  • Fatty Acids, Unsaturated
  • Fibronectins / metabolism
  • Humans
  • Hydrazines / pharmacology
  • Immunohistochemistry
  • Male
  • Mesenteric Arteries / drug effects
  • Mesenteric Arteries / physiology*
  • Mice
  • Mice, Knockout
  • Pyrazoles / pharmacology
  • Vascular Resistance / drug effects*

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Collagen Type I
  • Cyclooxygenase Inhibitors
  • Fatty Acids, Unsaturated
  • Fibronectins
  • Hydrazines
  • Pyrazoles
  • SC 560
  • Angiotensin II
  • 8-epi-prostaglandin F2alpha
  • 6-Ketoprostaglandin F1 alpha
  • SQ 29548
  • Elastin
  • Dinoprost
  • Cyclooxygenase 1